{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:fda-glp1-503b-bulks-list-proposal:v1","objectPathId":"fda-glp1-503b-bulks-list-proposal-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/fda-glp1-503b-bulks-list-proposal/","json":"https://peptidescanner.com/evidence/v1/objects/fda-glp1-503b-bulks-list-proposal-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/fda-glp1-503b-bulks-list-proposal-v1.md"},"story":{"slug":"fda-glp1-503b-bulks-list-proposal","version":1,"domain":"Regulatory","dateInSource":"2026-04-30","sourceCheckedAt":"2026-07-29","publishedAt":"2026-07-29","peptideSlugs":["semaglutide","tirzepatide","liraglutide"],"peptides":[{"slug":"semaglutide","url":"https://peptidescanner.com/peptides/semaglutide/"},{"slug":"tirzepatide","url":"https://peptidescanner.com/peptides/tirzepatide/"},{"slug":"liraglutide","url":"https://peptidescanner.com/peptides/liraglutide/"}]},"claims":[{"id":"headline","text":"FDA proposes excluding three GLP-1 ingredients from the 503B bulks list","sourceIds":["fda-glp1-bulks-proposal-2026"]},{"id":"summary","text":"FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use for compounding.","sourceIds":["fda-glp1-bulks-proposal-2026"]},{"id":"paragraph-1","text":"FDA announced a proposal concerning semaglutide, tirzepatide, and liraglutide and the 503B bulks list used by outsourcing facilities.","sourceIds":["fda-glp1-bulks-proposal-2026"]},{"id":"paragraph-2","text":"The agency action is a proposal, not a final rule or a statement that all compounding circumstances are identical. This update preserves that procedural distinction.","sourceIds":["fda-glp1-bulks-proposal-2026"]}],"sources":[{"id":"fda-glp1-bulks-proposal-2026","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list","url":"https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"8f05217c1556e94fb5c83b07ac3f1c90fd4c65095ff30fcc231c8de7b2351662"},"integrity":{"algorithm":"sha256","contentSha256":"9b689aad44877573fc601e9620170f769a22bcec89482f4dd2c319e61c54c1f6"}}